Featured Research

from universities, journals, and other organizations

Anti-rejection Nanotherapy Shows Promise In Rodent Lung Transplant Model

Date:
March 9, 2008
Source:
University of Texas Health Science Center at San Antonio
Summary:
Existing therapies for rejection of donor lungs can cause kidney damage. Just as some lung transplant patients celebrate the ability to breathe again, their immune systems begin to attack their new organ. This inflammatory autoimmune activity, called rejection, can lead to failure of the transplanted lungs. Of the people who receive new lungs each year, 30 percent to 40 percent will suffer an episode of rejection within a year of transplant.

Existing therapies for rejection of donor lungs can cause kidney damage.

Just as some lung transplant patients celebrate the ability to breathe again, their immune systems begin to attack their new organ.

This inflammatory autoimmune activity, called rejection, can lead to failure of the transplanted lungs. Of the people who receive new lungs each year, 30 percent to 40 percent will suffer an episode of rejection within a year of transplant.

A multidisciplinary team from The University of Texas Health Science Center at San Antonio, in collaboration with The University of Texas at Austin, is testing a novel nanoparticle aerosol therapy to prevent post-transplant rejection. The UT Health Science Center is home to one of the few research groups in the country studying solutions for this problem in a rodent model of lung transplant (rodent donor and recipient).

Conventional treatment of rejection includes high doses of prednisone and other anti-inflammatory medications that can harm the kidneys. “It is thought that if the therapy is inhaled, most will go to the lung, alleviating rejection and protecting the kidneys,” said Scott B. Johnson, M.D., associate professor of surgery in the UT Health Science Center Division of Cardiothoracic Surgery and principal investigator of the rodent lung transplant program.

Going beyond existing therapeutic aerosols, the UT Austin College of Pharmacy developed a formulation in which the aerosol particles are the size of nanometers (one billionth of a meter). This may help the 80 percent of patients who cannot inhale existing aerosols, Dr. Johnson said.

The chief collaborator from UT Austin is Robert O. Williams III, Ph.D., the Johnson & Johnson Centennial Professor of Pharmaceutics in the College of Pharmacy.

UT Health Science Center personnel have performed more than 200 rodent lung transplants, with 80 percent of the recipients surviving two weeks post-operatively, considered long-term survival in this rodent model.

The inch-wide surgical field is visualized using a high-strength microscope.

“Studies such as this are very difficult to perform in human subjects, in part because only a few thousand lung transplants are done in the U.S. annually,” said Clinton E. Baisden, M.D., professor and research director in the Division of Cardiothoracic Surgery.

Post-treatment analysis shows the nanoparticle aerosol concentration is very high in the lungs while concentrations elsewhere are much lower, Dr. Johnson said. The therapy will soon be tested in strains of rats bred to experience reproducible rejection at one week after transplant.

The Department of Medicine/Division of Pulmonary Diseases and the Department of Pathology at the UT Health Science Center provide key expertise toward the rodent lung transplant program, which is funded entirely through contributions from private benefactors.

“Several donors have made generous gifts to advance this important scientific effort,” said Jay I. Peters, M.D., professor of medicine/pulmonary diseases at the UT Health Science Center and a key collaborator on the project. “More than one of the donors has received a second chance at life through our lung transplant program, which is offered in conjunction with University Hospital (one of the UT Health Science Center's teaching hospitals). Now these wonderful individuals have joined forces with the Health Science Center to make lives better for future transplant patients.”

Dr. Johnson gives much of the credit for establishing the rodent lung transplant lab and perfecting the technique to Adam M. Cline, M.D., a research resident. Adham R. Saad, M.D., a third-year general surgery resident, works with Dr. Cline in the rodent lung transplant laboratory.

“Dr. Saad and I design the research under the division’s tutelage,” Dr. Cline said. “We enjoy performing these intricate surgeries in the hope that we can help lung transplant patients throughout the world.”


Story Source:

The above story is based on materials provided by University of Texas Health Science Center at San Antonio. Note: Materials may be edited for content and length.


Cite This Page:

University of Texas Health Science Center at San Antonio. "Anti-rejection Nanotherapy Shows Promise In Rodent Lung Transplant Model." ScienceDaily. ScienceDaily, 9 March 2008. <www.sciencedaily.com/releases/2008/03/080306220347.htm>.
University of Texas Health Science Center at San Antonio. (2008, March 9). Anti-rejection Nanotherapy Shows Promise In Rodent Lung Transplant Model. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2008/03/080306220347.htm
University of Texas Health Science Center at San Antonio. "Anti-rejection Nanotherapy Shows Promise In Rodent Lung Transplant Model." ScienceDaily. www.sciencedaily.com/releases/2008/03/080306220347.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins